Partnerships - Additional Information (Details) ¥ in Billions	1 Months Ended		3 Months Ended	6 Months Ended	31 Months Ended
	Dec. 31, 2022 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Nov. 30, 2019 shares	Aug. 03, 2023 USD ($)	Aug. 03, 2023 JPY (¥)	Dec. 05, 2022 USD ($)	Dec. 05, 2022 JPY (¥)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognized revenue			$ 9,124,000	$ 18,003,000
Deferred revenue current	$ 14,700,000		14,239,000	14,239,000
Deferred revenue long term	10,378,000		5,956,000	$ 5,956,000
Ono | Asset Purchase Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront non-refundable and non-creditable payment receivable, upon exchange of option								$ 26,400,000	¥ 3.5
One-time payment receivable, upon exercises the option						$ 34,800,000	¥ 5.0
Option period expiry condition				the option period will expire three months following the delivery of topline data from the EQUALISE clinical study in lupus nephritis and interim data from the EQUATOR Phase 3 clinical study in acute graft-versus-host disease.
Upfront non-refundable and non-creditable payment invoiced								25,800,000	¥ 3.5
Upfront payment received	26,400,000
Foreign curreny realized gain	$ 600,000
Initial transaction price								102,600,000
Upfront and non-creditable payment invoiced								25,800,000
Estimated research and development funding								76,800,000
Deferred revenue			20,200,000	$ 20,200,000				$ 25,800,000
Recognized revenue			9,100,000	18,000,000
Deferred revenue current			14,200,000	14,200,000
Deferred revenue long term			6,000,000	6,000,000
Proceeds from research and development fees				24,400,000
Ono | Asset Purchase Agreement | Research and Development Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognized revenue			6,800,000	13,500,000
Ono | Asset Purchase Agreement | Upfront Payment Amortization
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognized revenue			$ 2,300,000	$ 4,500,000
Ono | Asset Purchase Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payment on achievement of certain development milestones						$ 101,400,000
Biocon
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares issued | shares					2,316,134
Biocon | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory milestone payments		$ 30,000,000
Sales milestone payments		$ 565,000,000